AEON vs REVB vs JPM

JPMorgan Chase & Co.

(JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -100. 0% for Revelation Biosciences, Inc. (REVB). Over 10 years, the gap is even starker: JPM returned +465. 8% versus REVB's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AEON Biopharma, Inc.

(AEON) is the lower-risk stock at 0. 11β versus Revelation Biosciences, Inc. 's 1. 44β — meaning REVB is approximately 1266% more volatile than AEON relative to the S&P 500. On balance sheet safety, Revelation Biosciences, Inc. (REVB) carries a lower debt/equity ratio of 8% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Revelation Biosciences, Inc.

grew EPS 72. 7% year-over-year, compared to -105. 4% for AEON Biopharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 0% for Revelation Biosciences, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 0. 0% for REVB. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, JPM (1.

9% yield) pays a dividend. AEON, REVB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, REVB: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AEON (Healthcare) and REVB (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AEON is a small-cap quality compounder stock; REVB is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while AEON, REVB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.